BCRX
Price
$8.30
Change
-$0.16 (-1.89%)
Updated
Aug 29, 04:59 PM (EDT)
Capitalization
1.78B
61 days until earnings call
PBM
Price
$2.75
Change
-$0.22 (-7.41%)
Updated
Aug 29, 03:28 PM (EDT)
Capitalization
695.81K
Interact to see
Advertisement

BCRX vs PBM

Header iconBCRX vs PBM Comparison
Open Charts BCRX vs PBMBanner chart's image
BioCryst Pharmaceuticals
Price$8.30
Change-$0.16 (-1.89%)
Volume$39.65K
Capitalization1.78B
Psyence Biomedical
Price$2.75
Change-$0.22 (-7.41%)
Volume$400
Capitalization695.81K
BCRX vs PBM Comparison Chart in %
Loading...
BCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PBM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BCRX vs. PBM commentary
Aug 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCRX is a Hold and PBM is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 29, 2025
Stock price -- (BCRX: $8.47 vs. PBM: $2.97)
Brand notoriety: BCRX: Notable vs. PBM: Not notable
BCRX represents the Pharmaceuticals: Generic, while PBM is part of the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCRX: 57% vs. PBM: 7%
Market capitalization -- BCRX: $1.78B vs. PBM: $695.81K
BCRX [@Pharmaceuticals: Generic] is valued at $1.78B. PBM’s [@Biotechnology] market capitalization is $695.81K. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $68.6B to $0. The market cap for tickers in the [@Biotechnology] industry ranges from $100.52B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.84B. The average market capitalization across the [@Biotechnology] industry is $1.84B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCRX’s FA Score shows that 1 FA rating(s) are green whilePBM’s FA Score has 1 green FA rating(s).

  • BCRX’s FA Score: 1 green, 4 red.
  • PBM’s FA Score: 1 green, 4 red.
According to our system of comparison, BCRX is a better buy in the long-term than PBM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCRX’s TA Score shows that 5 TA indicator(s) are bullish while PBM’s TA Score has 2 bullish TA indicator(s).

  • BCRX’s TA Score: 5 bullish, 3 bearish.
  • PBM’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, BCRX is a better buy in the short-term than PBM.

Price Growth

BCRX (@Pharmaceuticals: Generic) experienced а +1.07% price change this week, while PBM (@Biotechnology) price change was -7.19% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +1.25%. For the same industry, the average monthly price growth was +68.20%, and the average quarterly price growth was +81.63%.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.74%. For the same industry, the average monthly price growth was +15.52%, and the average quarterly price growth was +29.97%.

Reported Earning Dates

BCRX is expected to report earnings on Oct 29, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+1.25% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

@Biotechnology (-0.74% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BCRX($1.78B) has a higher market cap than PBM($696K). BCRX YTD gains are higher at: 12.633 vs. PBM (-82.339). BCRX has higher annual earnings (EBITDA): 63.4M vs. PBM (-46.56M). BCRX has more cash in the bank: 260M vs. PBM (1.93M). PBM has less debt than BCRX: PBM (2.5M) vs BCRX (703M). BCRX has higher revenues than PBM: BCRX (558M) vs PBM (0).
BCRXPBMBCRX / PBM
Capitalization1.78B696K255,460%
EBITDA63.4M-46.56M-136%
Gain YTD12.633-82.339-15%
P/E RatioN/A0.07-
Revenue558M0-
Total Cash260M1.93M13,451%
Total Debt703M2.5M28,109%
FUNDAMENTALS RATINGS
BCRX: Fundamental Ratings
BCRX
OUTLOOK RATING
1..100
9
VALUATION
overvalued / fair valued / undervalued
1..100
32
Undervalued
PROFIT vs RISK RATING
1..100
79
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
61
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
BCRXPBM
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 3 days ago
80%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
Bullish Trend 2 days ago
73%
Bearish Trend 2 days ago
88%
MACD
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 17 days ago
79%
N/A
Declines
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
84%
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
50%
View a ticker or compare two or three
Interact to see
Advertisement
BCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PBM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BGCJX15.720.09
+0.54%
Baillie Gifford EAFE Plus All Cap 3
HGISX59.86N/A
N/A
Hartford Core Equity R4
MBCSX26.17N/A
N/A
MassMutual Blue Chip Growth R5
PLAAX16.43N/A
N/A
PACE Large Co Growth Equity A
FEMAX11.99N/A
N/A
First Eagle U.S. SMID Cap Opportunity A

PBM and

Correlation & Price change

A.I.dvisor indicates that over the last year, PBM has been loosely correlated with NEVPF. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if PBM jumps, then NEVPF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PBM
1D Price
Change %
PBM100%
-4.50%
NEVPF - PBM
54%
Loosely correlated
N/A
NRSN - PBM
36%
Loosely correlated
+1.79%
ATHA - PBM
28%
Poorly correlated
-1.13%
BCRX - PBM
27%
Poorly correlated
-0.59%
LQDA - PBM
25%
Poorly correlated
-1.93%
More